Clinical trial
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and…
NCT00398411 · University of Cologne, Other · Completed
Key facts
| NCT number | NCT00398411 |
|---|---|
| Title | Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells |
| Official title | Double-blind, Randomized, Mono-center, Placebo-controlled Pilot Study to Investigate the Efficacy and Safety of Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells |
| Acronym | MoxiProph |
| Lead sponsor | University of Cologne, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hodgkin Disease, Non-Hodgkin Lymphoma, Multiple Myeloma, Bacteremia |
| Intervention type | Drug |
| Interventions | moxifloxacin, placebo |
| Enrollment | 66 |
| Start date | Oct 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Nov 10, 2006 |
| Last update posted | Jun 29, 2015 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: